Grant of options
Oxford, UK -
22 November 2024: Oxford Biomedica plc
("OXB" or the "Company"; LSE: OXB), a quality and
innovation-led cell and gene therapy CDMO, today
announces the grant of an LTIP award under the OXB 2024 Long
Term Incentive Plan ("LTIP") to Mark Caswell, Site Head of UK
Operations.
In consideration of the grant of the
award, an RSU award previously granted to Mark Caswell on 3 October
2024 has been cancelled.
As with the LTIP awards granted on 3
October 2024 and in line with best practice, the award was scaled
back by 20%. The award is subject to the same performance
conditions as the awards granted on 3 October 2024.
The award will "vest" on 3 October
2027 to the extent determined by reference to the assessment of the
performance conditions and will be released at vesting.
The Notification of Dealing Forms
set out below are provided in accordance with the requirements of
the EU Market Abuse Regulation.
Notification of Dealing Form (1 of 2)
|
1.
|
Details of the
Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
|
|
a)
|
Name
|
Mark Caswell
|
|
2.
|
Reason for the
notification
|
|
a)
|
Position/status
|
Site Head of UK
Operations
|
|
b)
|
Initial notification/
amendment
|
Amendment
|
|
3.
|
Details of the
Issuer
|
|
a)
|
Name
|
Oxford Biomedica plc
|
|
b)
|
LEI code
|
213800S1GVQNXQ15K851
|
|
4.
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument
Identification code
|
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43
|
|
b)
|
Nature of the transaction
|
Cancellation of RSU award over 23,352
shares granted under the Company's Long Term Incentive
Plan.
|
|
c)
|
Price(s) and volumes(s)
|
RSU Award
|
Price
|
Volume (number of shares originally subject to
the RSU Award)
|
|
Nil
|
23,252
|
|
|
d)
|
Aggregated information
-
Aggregate volume
-
Price
|
23,352
N/A
|
|
e)
|
Date of the transaction
|
2024-11-22
|
|
f)
|
Place of the transaction
|
Outside of trading venue
|
Notification of Dealing Form (2 of 2)
|
1.
|
Details of the
Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
|
|
a)
|
Name
|
Mark Caswell
|
|
2.
|
Reason for the
notification
|
|
a)
|
Position/status
|
Site Head of UK
Operations
|
|
b)
|
Initial notification/
amendment
|
Initial notification
|
|
3.
|
Details of the
Issuer
|
|
a)
|
Name
|
Oxford Biomedica plc
|
|
b)
|
LEI code
|
213800S1GVQNXQ15K851
|
|
4.
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument
Identification code
|
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43
|
|
b)
|
Nature of the transaction
|
Grant of 53,724 LTIP award over Ordinary Shares
under the Company's Long Term Incentive Plan.
|
|
c)
|
Price(s) and volumes(s)
|
LTIP Award
|
|
d)
|
Aggregated information
-
Aggregate volume
-
Price
|
53,724
N/A
|
|
e)
|
Date of the transaction
|
2024-11-22
|
|
f)
|
Place of the transaction
|
Outside of trading venue
|
-Ends-
Enquiries:
|
Oxford Biomedica plc:
Natalie Walter, Company
Secretary
|
Tel: +44 (0)1865 783 000
|
About
OXB
OXB (LSE: OXB) is a quality and
innovation-led contract development and manufacturing organisation
(CDMO) in cell and gene therapy with a mission to enable its
clients to deliver life changing therapies to patients around the
world.
One of the original pioneers in cell
and gene therapy, OXB has more than 25 years of experience in viral
vectors; the driving force behind the majority of cell and gene
therapies. OXB collaborates with some of the world's most
innovative pharmaceutical and biotechnology companies, providing
viral vector development and manufacturing expertise in lentivirus,
adeno-associated virus (AAV), adenovirus and other viral vector
types. OXB's world-class capabilities span from early stage
development to commercialisation. These capabilities are supported
by robust quality-assurance systems, analytical methods and depth
of regulatory expertise.
OXB offers a vast number of unique
technologies for viral vector manufacturing, including a 4th
generation lentiviral vector system (the Tetravecta™ system), dual
plasmid system for AAV production, suspension and perfusion process
using process enhancers and stable producer and packaging cell
lines.
OXB, a FTSE4Good constituent, is
headquartered in Oxford, UK. It has bioprocessing and manufacturing
facilities across Oxfordshire, UK, Lyon and Strasbourg, France and
near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn
and YouTube.